These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 32975650

  • 1. Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
    Kispal B, Walker SAN.
    Eur J Clin Pharmacol; 2021 Feb; 77(2):197-205. PubMed ID: 32975650
    [Abstract] [Full Text] [Related]

  • 2. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
    Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, Korth-Bradley JM, Babinchak T, Ellis-Grosse E.
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
    [Abstract] [Full Text] [Related]

  • 3. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
    Isla A, Canut A, Arribas J, Asín-Prieto E, Rodríguez-Gascón A.
    Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE, Smith CL, Scharmen A, Kidd JM, Cooper C, Kuti J, Mitra S, Nicolau DP, Havlichek DH.
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [Abstract] [Full Text] [Related]

  • 7. Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae.
    Ji XW, Xue F, Kang ZS, Zhong W, Kuan IH, Yang XP, Zhu X, Li Y, Lv Y.
    Antimicrob Agents Chemother; 2020 Feb 21; 64(3):. PubMed ID: 31844001
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation.
    Dai Y, Chang W, Zhou X, Yu W, Huang C, Chen Y, Ma X, Lu H, Ji R, Ying C, Wang P, Liu Z, Yuan Q, Xiao Y.
    Drug Des Devel Ther; 2021 Feb 21; 15():2899-2905. PubMed ID: 34262257
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y, Jin L, Liu N, Luo X, Dong D, Tang J, Wang Y, You Y, Liu Y, Chen M, Yu Z, Hao Y, Gu Q.
    Int J Infect Dis; 2019 May 21; 82():79-85. PubMed ID: 30878630
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.
    Shoji K, Bradley JS, Reed MD, van den Anker JN, Domonoske C, Capparelli EV.
    Antimicrob Agents Chemother; 2016 Apr 21; 60(4):2150-6. PubMed ID: 26810655
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM, Zhang L, Hammel JP, Rubino CM, Bader JC, Sader HS, Gelone SP, Wicha WW, Ambrose PG.
    J Antimicrob Chemother; 2019 Apr 01; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [Abstract] [Full Text] [Related]

  • 17. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP, Pypstra R, Kahn JB, Murthy BP, Kimko HC, Bush K, Noel GJ, Drusano GL.
    Antimicrob Agents Chemother; 2007 Jul 01; 51(7):2378-87. PubMed ID: 17387149
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
    Samtani MN, Flamm R, Kaniga K, Nandy P.
    Antimicrob Agents Chemother; 2010 Jun 01; 54(6):2360-4. PubMed ID: 20385857
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA.
    Antimicrob Agents Chemother; 2001 Dec 01; 45(12):3468-73. PubMed ID: 11709326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.